You are here: Industry Insights > Dupixent

News List

FDA Grants Dupixent Breakthrough Therapy Designation for Eosinophilic Esophagitis americanpharmaceuticalreview
September 18, 2020
Regeneron Pharmaceuticals and Sanofi announced the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy designation to Dupixent? (dupilumab) for the treatment of patients 12 years and older with eosinophilic esophagitis (EoE).
Sanofi-Regeneron Dupixent secures China approval for atopic dermatitis pharmaceutical-technology
June 23, 2020
Sanofi and Regeneron Pharmaceuticals’ Dupixent (dupilumab) has received approval from China’s National Medical Products Administration (NMPA) to treat adults with moderate to severe atopic dermatitis.
Dupixent Eosinophilic Esophagitis Trial Meets Both Co-Primary Endpoints americanpharmaceuticalreview
June 01, 2020
Regeneron Pharmaceuticals and Sanofi announced positive results from Part A of the pivotal Phase 3 trial evaluating Dupixent? (dupilumab) in patients 12 years and older with eosinophilic esophagitis (EoE).
Sanofi unveils new data for Dupixent in children with dermatitis pharmatimes
April 03, 2020
Sanofi has unveiled more detailed late-stage data showing the benefit of biologic Dupixent (dupilumab) in a population of young patients with uncontrolled severe atopic dermatitis.
Dupixent Showed Positive Topline Results in Trial for Children americanpharmaceuticalreview
August 08, 2019
Regeneron and Sanofi announced a pivotal Phase 3 trial evaluating Dupixent? (dupilumab) to treat severe atopic dermatitis in children aged 6 to 11 years met its primary and secondary endpoints.
Regeneron's Sanofi deal finally turns a profit, thanks to Dupixent fiercepharma
August 07, 2019
More than 10 years after Sanofi and Regeneron joined forces in a high-profile?antibody drug partnership, the tie-up has recorded its first-ever profits—no thanks to the PCSK9 laggard Praluent, but with big bouquets for hard-driving Dupixent.
FDA Approves First Drug for Sinusitis With Nasal Polyps, Dupixent (Dupilumab) drugs
June 28, 2019
FDA Approves First Drug for Sinusitis With Nasal Polyps, Dupixent (Dupilumab).
Sanofi and Regeneron's Dupixent scores 3rd FDA approval in sinusitis with nasal polyps fiercepharma
June 28, 2019
Novartis' Xolair has also posted positive phase 3 data in chronic rhinosinusitis with nasal polyps, but hasn't yet scored any approvals for the use. GlaxoSmithKline is testing its Nucala in a phase 3 nasal polyps study.
Dupixent Approved for Chronic Rhinosinusitis With Nasal Polyps drugs
June 27, 2019
Dupixent Approved for Chronic Rhinosinusitis With Nasal Polyps.
FDA Approves Dupixent (dupilumab) for Chronic Rhinosinusitis with Nasal Polyposis drugs
June 27, 2019
FDA Approves Dupixent (dupilumab) for Chronic Rhinosinusitis with Nasal Polyposis.